Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS1
The NM_018062.4(FANCL):c.963T>A(p.Asp321Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000297 in 1,611,748 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
FANCL (HGNC:20748): (FA complementation group L) This gene encodes a ubiquitin ligase that is a member of the Fanconi anemia complementation group (FANC). Members of this group are related by their assembly into a common nuclear protein complex rather than by sequence similarity. This gene encodes the protein for complementation group L that mediates monoubiquitination of FANCD2 as well as FANCI. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2018]
Computational evidence support a benign effect (MetaRNN=0.01381591).
BP6
Variant 2-58161579-A-T is Benign according to our data. Variant chr2-58161579-A-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 241253.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Benign=1, Uncertain_significance=1}.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00161 (245/152044) while in subpopulation AFR AF= 0.00568 (236/41538). AF 95% confidence interval is 0.00509. There are 1 homozygotes in gnomad4. There are 112 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
Review Status: criteria provided, single submitter
Collection Method: curation
- -
Nov 18, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
not specified Uncertain:1
Apr 24, 2020
Genetic Services Laboratory, University of Chicago
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing
DNA sequence analysis of the FANCL gene demonstrated a sequence change, c.963T>A, in exon 12 that results in an amino acid change, p.Asp321Glu. This sequence change does not appear to have been previously described in patients with FANCL-related disorders and has been described in the gnomAD database with a population frequency of 0.54% in the African subpopulation; however, it has not been observed in homozygous state in any individuals (dbSNP rs140088149). The p.Asp321Glu change affects a highly conserved amino acid residue located in a domain of the FANCL protein that is not known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Asp321Glu substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Asp321Glu change remains unknown at this time. -
FANCL-related disorder Benign:1
Jun 23, 2021
PreventionGenetics, part of Exact Sciences
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Fanconi anemia complementation group L Benign:1
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Likely benign
Review Status: criteria provided, single submitter